Wednesday, May 27, 2026
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Apple Inc. (AAPL) and Micron Technology, Inc. (MU), as well as two micro-cap stocks Cumberland Pharmaceuticals Inc. (CPIX) and AmeriServ Financial, Inc. (ASRV). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Positive Sentiment in AI and Iran Keeps Pre-Market Buoyant
Today's Featured Research Reports
Alphabet’s shares have outperformed the Zacks Internet - Services industry over the past six months (+21.7% vs. +18.5%). The company’s AI-led product cycle continues to support growth across Search, Cloud and subscriptions. Search is benefitting from AI Overviews and AI Mode, which are driving higher usage and enabling new ad formats such as AI Max and direct offers in AI Mode.
Google Cloud is scaling faster as enterprises adopt AI infrastructure and AI solutions, and rising backlog provides better revenue visibility over the next two years. Paid subscriptions across Google One and YouTube keep expanding, supporting a more diversified revenue mix, while Waymo’s ride volumes point to steady progress in Other Bets.
Alphabet retains ample liquidity, but higher debt and elevated capital spending needs limit near-term flexibility and can create volatility in free cash flow. Overall, execution gains are balanced by spending, competition and legal risk.
(You can read the full research report on Alphabet here >>>)
Shares of Apple have gained +10.8% over the past six months against the Zacks Computer - Micro Computers industry’s gain of +13.3%. The company’s March quarter results showed demand for the iPhone 17 lineup and record Services revenue, supported by a growing installed base across major categories.
Management expects June quarter revenue growth in the mid-teens, with Services rising at a similar pace after adjusting for foreign exchange. New products such as iPhone 17e and MacBook Neo, plus Apple Business, can expand ecosystem engagement over time. Apple continues to return cash through dividends and buybacks, which can support the stock when operating results hold up.
At the same time, supply constraints, higher component costs and an uncertain tariff backdrop can weigh on availability and margins. Regulatory and legal actions tied to the App Store and antitrust claims also remain a risk factor, keeping the risk-reward balanced for a Neutral view.
(You can read the full research report on Apple here >>>)
Micron Technology’s shares have outperformed the Zacks Computer - Integrated Systems industry over the past six months (+279.2% vs. +112.9%). The company is benefiting from the rapidly expanding artificial intelligence (AI)-driven memory and storage markets. The positive impacts of inventory improvement across multiple end markets are driving top-line growth.
The surging demand for HBM and robust DRAM pricing recovery will aid significant revenue and earnings growth in the coming quarters. Its solid financials, positive free cash flow and strong balance sheet provide the flexibility to invest in growth initiatives while enhancing shareholder value.
Micron Technology’s long-term customer agreements and expanding AI partnerships reduce volatility and enhance revenue visibility. Nonetheless, rising operating costs and a massive increase in capital expenditure pose a downside risk to Micron’s near-term profitability.
(You can read the full research report on Micron Technology here >>>)
Shares of Cumberland Pharmaceuticals have outperformed the Zacks Medical - Drugs industry over the past six months (+155.3% vs. -12.7%). This microcap company with a market capitalization of $86.45 million is repositioning into a development-focused biotech through the monetization of its commercial portfolio via a strategic Apotex transaction, strengthening liquidity and reducing future commercial infrastructure costs.
The deal preserves upside through transition payments and potential milestone economics tied to Vibativ. The retained pipeline is anchored by ifetroban, a differentiated cardiovascular and rare disease asset with Fast Track designation in DMD-associated heart disease and multiple ongoing Phase II programs across DMD, systemic sclerosis, and IPF.
Meanwhile, established commercial brands such as Sancuso, Vibativ, and Caldolor continue to demonstrate market relevance and support operational stability. Expanded labeling for Caldolor and improving Vibativ execution further enhance the company’s strategic and clinical positioning.
(You can read the full research report on Cumberland Pharmaceuticals here >>>)
AmeriServ Financial’s shares have outperformed the Zacks Banks - Northeast industry over the past six months (+24.2% vs. +14.6%). This microcap company with a market capitalization of $64.46 million has seen its Q1'26 results highlighted improving earnings quality as lower funding costs and margin expansion supported net interest income growth. Deposits increased while FHLB borrowings declined, improving the funding mix and liquidity profile.
The company also benefits from a differentiated fee-based wealth management platform with $2.6 billion in administered assets and stable trust fees, supported by an expanded partnership with SB Value Partners to enhance operational efficiency. A conservative securities portfolio and solid core deposit mix further strengthen balance-sheet defensiveness.
However, profitability remains pressured by rising operating expenses, including elevated consulting and technology costs. Credit quality trends weakened as provisions, charge-offs, and stress in retail commercial real estate loans increased. The stock trades at 0.53X trailing book value.
(You can read the full research report on AmeriServ Financial here >>>)
Other noteworthy reports we are featuring today include Suncor Energy Inc. (SU), Public Service Enterprise Group Inc. (PEG) and AvalonBay Communities, Inc. (AVB).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Alphabet's (GOOGL) Prospects Rides on Cloud & Search Initiatives
Strong iPhone 17 & Services Growth to Aid Apple's (AAPL) Prospects
Rising AI Spending, Inventory Improvement Aid Micron (MU)
Featured Reports
Suncor (SU) Benefits From Its Resilient Integrated Energy Model
The Zacks analyst believes that Suncor's integrated assets and refining strength support stable margins during oil price swings, helping the company deliver reliable profits and durable cash flow.
Investments and Customer Growth Aid Public Service Enterprise (PEG)
Per the Zacks analyst, Public Service Enterprise strategic investments of $24-$28 billion through 2030 should help in system modernization. Customer growth will boost its performance.
Steady Demand & Development Aid AvalonBay (AVB), Interest Cost Hurt
Per the Zacks Analyst, AvalonBay benefits from steady demand in its high-barrier coastal markets. A healthy development pipeline would aid NOI addition. Yet high interest expenses raise concerns.
Robust Omnipod 5 Sales Aid Insulet (PODD) Amid Tough Competition
The Zacks analyst is bullish about the robust global uptake of Omnipod 5 - the only FDA-cleared, fully disposable pod-based AID system. Yet, a tough competitive landscape adds to the woes.
Clean Assets, North America Focus Aid Clearway Energy (CWEN)
Per the Zacks analyst Clearway Energy is gaining by generating electricity from renewable energy sources to meet rising demand and focus on domestic market saves it from currency risks.
Marathon Digital (MARA) Faces Asset Growth with Bitcoin Risk
Per Zacks, Marathon Digital effectively blends short-term Bitcoin income with long-term asset growth. Still, MARA is risky due to its heavy exposure to Bitcoin's volatility.
New Awards & Solid Backlog Aids Fluor (FLR) Amid Project Delays
Per the Zacks analyst, Fluor benefits from increased activities across nuclear power, LNG, mining, data centers and government programs and solid backlog. However, project delays are concerns.
New Upgrades
Lattice (LSCC) Rides on Strong Demand, Strategic Acquisition
Per the Zacks analyst, rising demand for AI servers, data center infrastructure, and computing applications will likely drive Lattice's top line. The buyout of AMI is expected to boost prospects.
DRAM and HBM Growth Continues to Aid Formfactor's (FORM) Prospects
Per the Zacks analysis, DRAM and HBM demand growth, rising test intensity, and HBM4 transition strength are expected to support FormFactor's margins and long-term prospects.
Improving Premium, Reinsurance Cover Drive Mercury General (MCY)
Per the Zacks analyst, Mercury General gains from rate increases and a higher number of policies written driving premiums higher. It also has a reinsurance program that protects against losses.
New Downgrades
High Input Costs & Challenging Markets to Hurt Astec Industries
The Zacks analyst is concerned that cost pressures from freight, duty and tariffs and persisting weakness in for forestry and mobile paving equipment will continue to weigh on Astec's results.
Clorox Faces Margin Pressure From Rising Cost Headwinds
Per the Zacks Analyst, Clorox faces margin pressure in fiscal 2026 as gross margin is expected to fall 250-300 basis points, driven by GOJO integration, ERP reversals and higher energy costs.
Challenges in Immunoglobulin Market Cloud ADMA's (ADMA) Prospects
Per the Zacks analyst, ADMA is grappling with heightened competitive dynamics across U.S. plasma-derived therapies and immunoglobulin market which creates near-term top-line pressure.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Apple Inc. (AAPL): Free Stock Analysis Report
AvalonBay Communities, Inc. (AVB): Free Stock Analysis Report
Public Service Enterprise Group Incorporated (PEG): Free Stock Analysis Report
Micron Technology, Inc. (MU): Free Stock Analysis Report
Suncor Energy Inc. (SU): Free Stock Analysis Report
Cumberland Pharmaceuticals Inc. (CPIX): Free Stock Analysis Report
Alphabet Inc. (GOOGL): Free Stock Analysis Report
AmeriServ Financial Inc. (ASRV): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).